Dr. Danila on how he chooses among androgen receptor inhibitors in castration-resistant prostate cancer

Video

Daniel C. Danila, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses choosing among the androgen receptor inhibitors darolutamide (Nubeqa), enzalutamide (Xtandi), and apalutamide (Erleada) when treating patients with castration-resistant prostate cancer.

Related Videos
Samuel L. Washington III, MD, answers a question during a Zoom video interview
Experts on prostate cancer
Amir H. Lebastchi, MD, an expert on prostate cancer
Amir H. Lebastchi, MD, an expert on prostate cancer
Experts on prostate cancer
Edward M. Schaeffer, MD, PhD, answers a Zoom video interview question
Man talking with doctor | Image Credit: © Chinnapong - stock.adobe.com
Paul M. Yonover, MD, FACS, an expert on prostate cancer
Related Content
© 2023 MJH Life Sciences

All rights reserved.